Bahl & Gaynor Inc. Raises Position in Zoetis Inc. $ZTS

Key Points

• Bahl & Gaynor Inc. increased its stake in Zoetis Inc. by 51.4% during the first quarter, now holding 246,454 shares valued at approximately $40.58 million.
• Zoetis recently reported earnings of $1.76 EPS, surpassing analysts' expectations of $1.62, with a 4.2% year-over-year revenue growth.
• Research analysts have mixed ratings on Zoetis, with price targets ranging from $155 to $215, indicating differing outlooks on the stock's performance.

Bahl & Gaynor Inc. boosted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 51.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 246,454 shares of the company's stock after buying an additional 83,646 shares during the period. Bahl & Gaynor Inc. owned approximately 0.06% of Zoetis worth $40,579,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Biondo Investment Advisors LLC grew its stake in Zoetis by 1.2% in the 1st quarter. Biondo Investment Advisors LLC now owns 18,012 shares of the company's stock valued at $2,966,000 after buying an additional 220 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Zoetis by 8.3% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 320,203 shares of the company's stock valued at $52,721,000 after buying an additional 24,462 shares in the last quarter. Haverford Trust Co grew its stake in Zoetis by 0.5% in the 1st quarter. Haverford Trust Co now owns 127,098 shares of the company's stock valued at $20,927,000 after buying an additional 665 shares in the last quarter. Groupe la Francaise grew its stake in Zoetis by 131.6% in the 1st quarter. Groupe la Francaise now owns 19,268 shares of the company's stock valued at $3,018,000 after buying an additional 10,947 shares in the last quarter. Finally, Douglass Winthrop Advisors LLC grew its stake in Zoetis by 3.5% in the 1st quarter. Douglass Winthrop Advisors LLC now owns 481,488 shares of the company's stock valued at $79,277,000 after buying an additional 16,119 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.5%

ZTS opened at $156.3180 on Friday. The stock has a market cap of $69.28 billion, a PE ratio of 26.91, a P/E/G ratio of 2.50 and a beta of 0.88. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The business's fifty day simple moving average is $153.84 and its 200 day simple moving average is $158.64.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $202.43.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.